Ophthalmology

A proprietary vector discovery platform called Therapeutic Vector Evolution sits at the centre of 4DMT 's approach to genetic medicine. Rather than relying on existing delivery vehicles, the clinical-stage biopharma company engineers customised, proprietary gene delivery vectors matched to specific tissue types and routes of administration, with the goal of addressing large-market diseases where conventional treatments fall short. Founded in 2015 and headquartered in Emeryville, California, 4DMT trades on NASDAQ under the ticker FDMT. 4DMT's integrated product engine spans design, development and manufacturing, enabling the company to build a diverse clinical pipeline. Current therapeutic focus spans retinal diseases and pulmonary diseases, two areas with significant unmet need in which precision gene delivery to targeted tissue is critical. The company positions its work as striving for potential curative outcomes rather than symptomatic management, reflecting its stated ambition to unlock the full potential of genetic medicine. As a clinical-stage organisation, 4DMT combines platform innovation with pipeline execution, maintaining a scientific advisory structure that includes a dedicated Retina Advisory Board alongside broader scientific and corporate advisory boards. The company also supports internal diversity through its 4Diversity programme, which shapes workforce culture and recruitment practices. Further information is available at 4dmoleculartherapeutics.com.

Astellas Europe represents the regional operations of Astellas Pharma Inc., a Japanese global pharmaceutical company formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. Listed on the Tokyo Stock Exchange (ticker: 4503) and employing approximately 14,000 people worldwide, Astellas positions itself at the intersection of rigorous science and patient-centred value creation, with its European presence playing a significant role in clinical development, commercial operations, and medical affairs across the region. Therapy Areas and Commercial Portfolio The company's established commercial portfolio reflects a focused strategy across several specialist areas. In oncology and urology, enzalutamide (marketed as Xtandi) for metastatic prostate cancer stands as one of the group's flagship medicines, developed in partnership with Pfizer. Transplantation medicine remains a historical strength, with tacrolimus (Prograf) continuing to serve patients requiring immunosuppression following organ transplant. Overactive bladder is addressed through mirabegron (Betmiga), a beta-3 adrenoceptor agonist that expanded treatment options beyond established anticholinergic therapies. These products underpin the European business while the pipeline advances next-generation candidates. Research Priorities and Open Innovation Astellas concentrates its research investment on four primary scientific focuses: blindness and regeneration, genetic regulation, immuno-oncology , and targeted protein degradation . Drug discovery capabilities support candidate progression from early research through clinical trials, and external funding partnerships broaden the scope of scientific enquiry beyond internal capacity. Open innovation platforms, including the SakuLab facilities in Tsukuba and Cambridge and the TME iLab initiative, provide frameworks for collaboration with external researchers and institutions. Patient centricity is embedded structurally across the organisation, combining patient partnerships, medical intelligence, behavioural science expertise, and patient insights into a coherent programme that informs both the direction of science and standards of corporate governance. Manufacturing and supply operations complement the research enterprise, supporting the integrated model from discovery to commercial availability across European markets. Further information is available at astellas.com/eu/.

Bayer is one of the oldest and most globally recognised life sciences companies in the world, founded in Barmen, Germany in 1863 and responsible for introducing aspirin to modern medicine. Today the company operates across more than 100 countries, employing tens of thousands of people and generating revenues in the tens of billions of euros annually, with its shares listed on the Frankfurt Stock Exchange under the ticker BAYN. Pharmaceuticals Division Bayer's pharmaceuticals business focuses on four core therapeutic areas: cardiovascular disease, oncology, gynaecology, and ophthalmology. The company's cardiovascular portfolio is among the most recognised in the industry, anchored by Xarelto (rivaroxaban), one of the world's most widely prescribed oral anticoagulants. In oncology, Bayer has built a substantial presence in targeted therapies, including treatments for renal cell carcinoma and thyroid cancer. The division also holds a strong position in women's health, with a broad contraception and fertility product range distributed globally. Crop Science & Consumer Health Beyond pharmaceuticals, Bayer operates one of the world's largest crop science divisions, a segment significantly expanded following the acquisition of Monsanto in 2018. This business covers herbicides, fungicides, insecticides, and seeds, making Bayer a central player in global agricultural supply chains. The company's consumer health division, which markets established brands in pain relief, dermatology, nutritional supplements, and allergy care, was partially divested through a strategic review, reflecting Bayer's continued focus on its prescription and crop science core. Bayer's research and development investment spans biologics, cell and gene therapy, and radiopharmaceuticals, with the company actively expanding its pipeline through both internal programmes and external partnerships and acquisitions. Its global headquarters remain in Leverkusen, Germany, where the company was formally established. Further information is available at bayer.com.

Novartis ranks among the world's largest pharmaceutical companies, built on the 1996 merger of Ciba-Geigy and Sandoz, two Swiss chemical and pharmaceutical giants with roots stretching back to the nineteenth century. Headquartered in Basel, Switzerland, the company operates across more than 100 countries and employs hundreds of thousands of people globally, making it one of the defining organisations in modern medicine. Innovative Medicines The core innovative medicines division focuses on developing and commercialising patented treatments across a concentrated set of therapeutic areas. Oncology is a particular strength, with the company having established early leadership in targeted cancer therapies, including kinase inhibitors that reshaped haematology. Cardiovascular, immunology, neuroscience, and ophthalmology round out the primary focus areas. The company's cell and gene therapy ambitions are embodied in platforms that have drawn significant industry attention, positioning Novartis at the frontier of advanced therapeutic modalities. Sandoz & the Generics Legacy For much of its post-merger history, Novartis operated a substantial generics and biosimilars business under the Sandoz brand. In 2023, Sandoz was spun off as an independent publicly traded company, sharpening Novartis's focus entirely on patented innovative medicines. The separation reflected a broader strategic decision to concentrate resources where the company sees its strongest long-term competitive position. Novartis is listed on the SIX Swiss Exchange under the ticker NOVN and on the New York Stock Exchange as NVS, giving it access to deep capital markets to fund its substantial research and development programme. The company consistently ranks among the top spenders on pharmaceutical R&D globally, operating research facilities across Europe, North America, and Asia. Radioligand therapy represents one of the newer strategic bets, combining targeted delivery mechanisms with therapeutic isotopes, an area Novartis has pursued through acquisitions and internal development. The company's commercial pipeline and approved portfolio span small molecules, biologics, and cell-based therapies, reflecting the breadth of its scientific capabilities. Further information is available at novartis.com.

Regeneron Pharmaceuticals built one of the most productive drug-discovery engines in the industry, turning its proprietary VelociSuite technology platform into a stream of approved medicines across immunology, oncology, ophthalmology, and rare disease. VelociSuite: The Engine Behind the Pipeline Founded in 1988 and headquartered in Tarrytown, New York, Regeneron developed VelociSuite as a set of integrated technologies for generating fully human antibodies at speed and scale. VelocImmune, the flagship component, replaced mouse immune systems with human equivalents, dramatically improving the translatability of antibody candidates from preclinical work into clinical development. This approach underpins the majority of Regeneron's approved portfolio and its extensive collaboration pipeline. Approved Portfolio and Collaboration Network The company's commercial portfolio includes treatments for atopic dermatitis, asthma, chronic sinusitis with nasal polyps, high cholesterol , wet age-related macular degeneration, diabetic eye disease, cervical cancer, and rare blood disorders, among other indications. Dupixent, co-developed and co-commercialised with Sanofi, became one of the best-selling medicines globally and continues to be studied across a broad range of type 2 inflammatory conditions. Eylea, targeting vascular endothelial growth factor, remains a leading treatment in retinal disease. Regeneron's long-standing alliance with Sanofi covers immunology and oncology, while the company maintains an oncology collaboration with Bayer centred on cancer therapy. The company also operates Regeneron Genetics Center, one of the largest human genetics programmes in the world, partnering with health systems to sequence patient genomes and identify novel drug targets. Listed on Nasdaq under the ticker REGN, Regeneron employs tens of thousands of people globally, with significant research and manufacturing infrastructure concentrated in New York State. Further information is available at regeneron.com.

Founded in 1896 in Basel, Switzerland, Roche has spent more than a century developing medicines and diagnostic tests that together address some of the most complex conditions in modern healthcare. Listed on the SIX Swiss Exchange and a constituent of the Swiss Market Index, the company is one of the world's largest healthcare businesses by revenue. Operating across two complementary divisions, Pharma and Diagnostics, Roche occupies a distinctive position in the global industry: it is one of very few organisations that integrates therapeutic development with the in-vitro diagnostics capability to inform and monitor those same therapies. Therapeutic Focus Across Major Disease Areas Roche's pharmaceutical pipeline and marketed portfolio span a broad range of therapeutic areas, including oncology , haematology, neurology, ophthalmology, immunology, infectious diseases, inflammatory bowel diseases, cardiometabolic conditions, diabetes, respiratory disease, and women's health. This breadth reflects decades of investment in both internal research and external partnering, reinforced by the 2009 full acquisition of Genentech, which significantly expanded the company's biologics and personalised medicine capabilities. Roche maintains defined ethical standards and a structured innovation process to guide candidate selection and clinical development. Diagnostics as a Strategic Complement The Diagnostics division is widely recognised as the world's largest in-vitro diagnostics business and develops solutions that support clinical decision-making across many of the same disease areas addressed by the Pharma arm. Safety reporting infrastructure and dedicated support for safety officers form part of the diagnostic solutions offering, reinforcing the company's commitment to pharmacovigilance and patient safety throughout the product lifecycle. This integration of drug and diagnostic development is a long-standing strategic pillar at Roche, enabling a personalised healthcare approach that aligns diagnostic insight with therapeutic intervention. Governance at Roche is structured around a Board of Directors, an Executive Committee, and formal board committees, with an Annual General Meeting providing shareholder oversight. The company publishes sustainability goals, ESG performance data, and safety, health and wellbeing metrics as part of its public reporting. Community investment is channelled through the Roche Global Citizenship programme, which covers arts and culture, community disaster relief, humanitarian and social development, and science education initiatives. Further information is available at roche.com.